Practice Management of Ulcerative Colitis in 2015
Gastroenterology
Curriculum:
Practice Management of IBD
Practice Management of IBD
Credits:
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
June 30, 2015
June 30, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Gastroenterologists; Nurse Practitioners; Nurses and Physician assistants who work with gastroenterology practices and/or treat patients with IBD; Pharmacists
Relevant Terms:
Ulcerative Colitis; Crohn's disease; inflammatory bowel disease
Stephen Hanauer, MD
Stephen Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Northwestern Medicine
Chicago, IL
Bio
Stephen B. Hanauer is currently President of the American College of Gastroenterology. He completed a medical degree, with honors, at the University of Illinois in Chicago. His postdoctoral training included an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at the University of Chicago. He rose through academic ranks to become Professor of Medicine and subsequently was awarded the Joseph B. Kirsner Chair in Medicine and was designated Chief of the Section of Gastroenterology, Hepatology and Nutrition where he served from 2000-2014. He was recruited as the Medical Director of the Digestive Health Center at Northwestern Medicine and is Clifford Joseph Barborka Professor of Medicine in the Northwestern Feinberg School of Medicine as of January 1, 2014.Dr. Hanauer is board certified in internal medicine and gastroenterology by the American Board of Internal Medicine and the American Board of Gastroenterology, respectively. He holds membership in several professional societies and is a Fellow of American Gastroenterological Association, the American College of Gastroenterology and the American College of Physicians. In connection with the American Gastroenterological Association (AGA), Dr. Hanauer served as chair for the Inflammation, Immunology, and Inflammatory Bowel Disease Section and the Clinical Practice Section and subsequently served as Councilor for Clinical Research on the AGA Governing Board. He is a prior member of the Specialty Board of the American Board of Internal Medicine. Among his many honors, Dr. Hanauer received the AGA Fiterman Foundation Joseph B. Kirsner Award in Gastroenterology in 2001 and the Janssen Award for Clinical Excellence in 2004. He has served as a Member and Chair of the U.S. Food and Drug Administration Advisory Panel for Gastrointestinal Disorders and is a member and former-Chairman of the International Organization for Inflammatory Bowel Disease.
Dr. Hanauer has authored hundreds of peer-reviewed journal articles, books and book chapters, abstracts, monographs, and editorials. Dr. Hanauer is ex-Editor-in-Chief of Nature Clinical Practice Gastroenterology & Hepatology and currently serves as Associate Editor (IBD) of Clinical Gastroenterology and Hepatology. He is also a member of the editorial boards of numerous journals, including the American Journal of Gastroenterology, and Inflammatory Bowel Diseases.
| 1. | Articulate increased confidence in the identification of CD and UC disease and recognize which patients will or will not likely benefit from use of biological therapies | 2. | Decide when patients will likely benefit from the use of biological therapies |
| 3. | List both the benefits and the risks of biological therapies | 4. | Describe increased competence in their ability to monitor patients with IBD who are on biologic therapies |
| 1. | Articulate increased confidence in the identification of CD and UC disease and recognize which patients will or will not likely benefit from use of biological therapies |
| 2. | Decide when patients will likely benefit from the use of biological therapies |
| 3. | List both the benefits and the risks of biological therapies |
| 4. | Describe increased competence in their ability to monitor patients with IBD who are on biologic therapies |
Course Director
Francis A. Farraye, MD, MSc
Course Director
Professor of Medicine, Boston University School of Medicine
Clinical Director, Section of Gastroenterology, Boston Medical Center (Boston, MA)
Professor of Medicine, Boston University School of Medicine
Clinical Director, Section of Gastroenterology, Boston Medical Center (Boston, MA)
DISCLOSURE POLICY STATEMENT
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Faculty Disclosures
Stephen Hanauer, MD is a consultant Abbvie, Actavis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Ferring, Hospira, Janssen, Luitpold/American Regent, Nestle, Pfizer, Prometheus, Receptos, Salix, Shire, Takeda and UCB Pharma. He is also a clinical researcher for Abbvie, Amgen, Janseen, Luitpold/American Regent, Pfizer, Prometheus, Receptos, Takeda and UCB Pharma. He is also a speaker for Abbvie, Jansseen and Takeda and is a member of Bristol Myer Squibb’s Data and Safety Monitoring Board.
Off-Label Discussions
The faculty member does plan on discussing unlabeled/investigational uses of a commercial product. The use of thiopurines and methotrexate for treating Ulcerative colitis (including combination therapy) has not received labeling approval despite supportive literature. Please note there is approval for biologics for patients who have failed immune suppressives.
Planning Committee Disclosures
Michael Burk, Senior Program Manager, Boston University School of Medicine’s Continuing Medical Education Department, has nothing to disclose in regards to commercial support.
Ms. Patti-Ann Collins, Boston University’s Continuing Medical Education department’s Lead Nurse Planner, has nothing to disclose with regards to commercial support.
Frank Farraye, MD, our program course director, is a consultant for Abbvie, Braintree, Extract, Janseen, Pfizer and Takeda. He also receives grant/research support from Cubist, Exact and Prometheus.
Hannah Miller, MD Boston University’s Continuing Medical Education department’s independent CME content reviewer, has nothing to disclose with regards to commercial support.
Beth-Ann Norton, MS, RN, ANP-BC, Nursing Program Director for the Crohn's and Colitis Center Adult Nurse Practitioner Brigham & Women's Hospital, and BUSM’s nursing advisor for this activity, is a consultant for Abbvie and NPS/Shire.
DISCLOSURE ATTESTATION
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.
DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
Non-Endorsement of Products
Continuing Nursing Education Provider Unit, Boston University School of Medicine’s provider status refers only to continuing nursing education activities and does not imply that there is real or implied endorsement by Continuing Nursing Education Provider Unit, Boston University School of Medicine or ANCC of any product, service, or company referred to in this activity nor of any company subsidizing costs related to the activity.
CREDIT DESIGNATION
Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACCREDITATION STATEMENT
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CNE Contact Hours: 1.0 all of which are eligible for pharmacology credit.
Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CNE Contact Hours: 1.0 all of which are eligible for pharmacology credit.
Nurses will receive contact hours after completion of an evaluation and claim for credit form.
Continuing Pharmacy Education CreditsThe University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Attendance and completion of program evaluations at the conclusion of the program are required for a statement of credit. This knowledge-based activity is approved for 1.0 Contact Hours (0.1 CEUs). UAN: 0060-9999-15-026-H01-P. Expiration date: June 29th, 2016.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, nurses are entitled to receive 1.00 CNE contact hours, all of which is pharmacology credit worthy, and pharmacists will receive 1.0 Contact Hours(0.1 CEUs). Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians, nurses and pharmacists who successfully complete the post-test and evaluation will resepectively receive CME, CNE or ACPE credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
*Note to Pharmacists: to receive CE credits you must submit your NABP ID number. You will be prompted to submit your ID number at the end of the activity, after completing the posttest, when claiming your credits. This is mandatory and the CE credits are not valid unless an NABP ID is submitted.
If you do not have an ID number you can obtain one at the following link:
Release Date: June 30, 2015
Expiration Date: June 29, 2016
Expiration Date: June 29, 2016
Date of Most Recent Review: June 30, 2015
Program Code: E.IBD15UC
For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
To view Boston University’s Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.
COMMERCIAL SUPPORT
This continuing medical education activity is supported by independent educational grants from Abbvie Inc., Takeda Pharmaceuticals International Inc. and from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
